对胰腺癌中的KRAS异常进行全面分析,重点关注预后和治疗影响
Jaeyun Jung1,2, Jung Yong Hong3, Se Hoon Park3
1Department of Biochemistry, College of Medicine, Chungbuk National University, Chungbuk, South Korea.
Therapeutic advances in medical oncology
|August 20, 2025
概括
在先进的固体瘤中,KRAS异常很常见,像G12D这样的单核酸变体 (SNV) 最常见. 特定突变,如G12V和G13D,与较差的患者存活率有关.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- KRAS是人类癌症中经常发生突变的癌基因.
- 克拉斯异常显著影响各种固体瘤的预后和治疗.
研究的目的:
- 识别和描述KRAS中的遗传变化,包括单氨基酸替代和放大.
- 分析KRAS突变在先进的实体瘤中的频率和分布.
- 研究KRAS突变类型与患者存活率之间的相关性.
主要方法:
- 对1667名先进固体瘤患者进行了回顾性队列研究.
- 下一代测序 (NGS) 用于识别KRAS中的遗传变化.
- 统计分析以确定突变发生率,类型和生存影响.
主要成果:
- 在28.1%的患者 (468/1667) 中发现了KRAS异常.
- 单核酸变异 (SNVs) 比放大 (2.9%) 更常见 (26.1%).
- 胰腺癌显示SNV发病率最高 (89.9%). G12D (40.6%) 是最常见的突变,其次是G12V (21.7%) 和G13D (10.7%).
- G12V和G13D突变与患者生存率显著降低有关.
结论:
- 在转移性实体瘤中,KRAS异常很普遍,在癌症类型中具有不同的突变概况.
- 特定的KRAS突变 (G12V,G13D) 是低生存率的预后标志物.
- 了解KRAS改变模式对于指导固体瘤的向治疗至关重要.
相关概念视频
Cancer Survival Analysis
445
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
445
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K


